ReviewWorld journal of gastroenterology2016
Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 67 citations in OpenAlex.
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
- Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.BMC cancer · 2024Article
- The Potential of Salivary Biomarkers in Early Detection of Pancreatic Ductal Adenocarcinoma: A Systematic Review.Cureus · 2024Review
- Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis.American journal of cancer research · 2024Article
- Cell-free DNA as a prognostic and predictive biomarker in resectable distal common bile duct cancer.Journal of the Chinese Medical Association : JCMA · 2023Article
- Review
- Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer.Biomedicines · 2023Review
- Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients.Biomedicines · 2022Article
- Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.Frontiers in oncology · 2022Article
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- Development and validation of a flexible DNA extraction (PAN) method for liquid biopsy of multiple sample types.Journal of clinical laboratory analysis · 2021Article
- Machine Learning Protocols in Early Cancer Detection Based on Liquid Biopsy: A Survey.Life (Basel, Switzerland) · 2021Review
- Article
- Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?Cancers · 2021Review
- Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer.Journal of oncology · 2021Article
- Clinical Perspective and Translational Oncology of Liquid Biopsy.Diagnostics (Basel, Switzerland) · 2020Review
- Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?International journal of molecular sciences · 2020Review
- Application of liquid biopsy for surgical management of pancreatic cancer.Annals of gastroenterological surgery · 2020Review
- Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers.Diagnostics (Basel, Switzerland) · 2020Review
- Exosomal biomarkers for cancer diagnosis and patient monitoring.Expert review of molecular diagnostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances in surgical techniques and perioperative management, the prognosis of pancreatic cancer (PCa) remains extremely poor. To provide optimal treatment for each patient with Pca, superior biomarkers are urgently needed in all phases of management from early detection to staging, treatment monitoring, and prognosis. In the blood of patients with cancer, circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs), such as DNA, mRNA, and noncoding RNA have been recognized. In the recent years, their presence in the blood has encouraged researchers to investigate their potential use as novel blood biomarkers, and numerous studies have demonstrated their potential clinical utility as a biomarker for certain types of cancer. This concept, called "liquid biopsy" has been focused on as a less invasive, alternative approach to cancer tissue biopsy for obtaining genetic and epigenetic aberrations that contribute to oncogenesis and cancer progression. In this article, we review the available literature on CTCs and cfNAs in patients with cancer, particularly focusing on PCa, and discuss future perspectives in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.